Stress Urinary Incontinence

1. Overview

Stress urinary incontinence (SUI) is defined by the International Continence Society (ICS) as the involuntary leakage of urine on effort or physical exertion (e.g., sporting activities), or on sneezing or coughing. [1] This condition represents the most prevalent form of urinary incontinence in women, with profound implications for quality of life, psychological wellbeing, and healthcare utilisation.

SUI occurs when the intravesical pressure exceeds the maximum urethral closure pressure in the absence of detrusor muscle contraction. The underlying pathophysiology involves either urethral hypermobility (failure of anatomical support) or intrinsic sphincter deficiency (ISD), with most patients demonstrating a combination of both mechanisms. [2]

The clinical significance of SUI extends beyond mere inconvenience. Systematic reviews demonstrate that women with SUI experience significantly higher rates of depression, anxiety, social isolation, and sexual dysfunction compared to continent controls. [3] The economic burden is substantial, with direct healthcare costs and indirect costs from lost productivity estimated at billions annually in developed nations.

Clinical Pearl: The "Hammock Hypothesis": DeLancey's hammock theory (1994) revolutionised our understanding of continence. The urethra does not close by its own strength alone; rather, it is compressed against a supportive layer of endopelvic fascia and the anterior vaginal wall during increases in abdominal pressure. When this "hammock" is weakened or displaced, the urethra descends and remains patent during stress, allowing leakage. [4]

---

2. Epidemiology

Prevalence and Incidence

The epidemiology of SUI presents significant heterogeneity across studies due to varying definitions, populations, and assessment methods. However, robust data from large population-based cohorts provide reliable estimates.

The Norwegian EPINCONT study, one of the largest population-based surveys (n=27,936), reported that 50% of incontinent women had stress incontinence as the predominant type, with prevalence increasing with age but plateauing after age 50. [5]

Risk Factor Analysis

Risk factors for SUI are well-established through multiple prospective cohort studies and meta-analyses.

Obstetric Factors

Vaginal delivery remains the strongest modifiable risk factor for SUI. The mechanism involves direct trauma to pelvic floor muscles, fascial supports, and pudendal nerve injury during passage through the birth canal.

A landmark Swedish cohort study following 5,236 primiparous women demonstrated that mode of delivery significantly influences long-term continence: 10 years postpartum, SUI affected 29% of women delivered vaginally versus 16% delivered by caesarean section. [6]

Non-Obstetric Factors

Exam Detail: Genetic Susceptibility: Twin studies demonstrate a heritability of 40-55% for SUI, suggesting substantial genetic contribution. Candidate genes include those encoding collagen (COL1A1, COL3A1), matrix metalloproteinases (MMP-1, MMP-9), and oestrogen receptors (ESR1). Polymorphisms in collagen genes correlate with altered tissue strength and increased SUI risk. [7]

Obesity: The Modifiable Giant

The PRIDE (Program to Reduce Incontinence by Diet and Exercise) trial demonstrated that weight loss of 8% body weight at 6 months resulted in a 47% reduction in weekly incontinence episodes compared to 28% in controls. [8] This represents the strongest evidence for lifestyle intervention in SUI management.

---

3. Pathophysiology

The Continence Mechanism

Urinary continence requires a functional urethral closure mechanism that maintains intraurethral pressure above intravesical pressure during both rest and physical stress. This involves an integrated system of:

1. Intrinsic urethral factors: Smooth muscle, striated muscle (rhabdosphincter), vascular plexus, and mucosal coaptation
2. Extrinsic support: Pubourethral ligaments, endopelvic fascia, levator ani muscles
3. Neural control: Pudendal nerve (somatic), pelvic nerves (autonomic)

The Hammock Theory (DeLancey)

DeLancey's integral theory of continence (1994) explains the mechanism of stress continence through the "hammock" concept. [4]

Normal Continence:

1. The urethra rests on a supportive layer composed of the anterior vaginal wall and endopelvic fascia
2. This layer is attached laterally to the arcus tendineus fasciae pelvis (ATFP)
3. During increases in abdominal pressure, the proximal urethra is compressed against this supportive layer
4. The "hammock" acts as a backstop, creating urethral compression and maintaining continence

Mechanism of Incontinence:

1. When support is weakened (childbirth, menopause, connective tissue disorders), the hammock sags
2. The proximal urethra descends below the zone of pressure transmission
3. Abdominal pressure increases intravesical pressure but fails to compress the urethra
4. Net result: Bladder pressure exceeds urethral pressure, causing leakage

Two Pathophysiological Subtypes

Type 1: Urethral Hypermobility

The predominant mechanism in most women with SUI, urethral hypermobility results from loss of urethral support. The urethra and bladder neck descend during straining due to:

• Damage to the pubourethral ligaments
• Weakness of the pubococcygeus muscle (levator ani)
• Disruption of the endopelvic fascia
• Detachment from the arcus tendineus fasciae pelvis

Clinical Correlates:

• Q-tip test: Angle change > 30 degrees from horizontal indicates hypermobility
• Valsalva leak point pressure (VLPP): Typically > 90 cmH2O
• Responds well to surgical correction with continence procedures

Type 2: Intrinsic Sphincter Deficiency (ISD)

ISD represents failure of the urethral closure mechanism itself, independent of support. The urethra remains open at rest, functioning as a "drainpipe" with minimal resistance.

Causes of ISD:

• Previous anti-incontinence surgery (scarring)
• Pelvic radiotherapy
• Radical pelvic surgery (hysterectomy, colorectal resection)
• Neurological conditions affecting the sphincter
• Advanced age with muscle atrophy
• Severe oestrogen deficiency

Clinical Correlates:

• Low Valsalva leak point pressure (less than 60 cmH2O)
• Open bladder neck at rest on urodynamics
• Fixed, non-mobile urethra (scarring)
• Responds less well to conventional slings
• May require bulking agents or artificial urinary sphincter

Exam Detail: Molecular Pathophysiology of Pelvic Floor Weakness

The extracellular matrix (ECM) of the pelvic floor undergoes significant remodelling in SUI. Key molecular changes include:

1. Collagen Alterations:

   • Decreased total collagen content (up to 30% reduction)
   • Shift from Type I (strong) to Type III (elastic) collagen ratio
   • Increased matrix metalloproteinase (MMP-1, MMP-2, MMP-9) activity
   • Reduced tissue inhibitors of metalloproteinases (TIMPs)

2. Elastin Degradation:

   • Fragmentation of elastin fibres
   • Loss of elastic recoil in vaginal wall and supports
   • Increased elastase activity

3. Smooth Muscle Changes:

   • Reduced smooth muscle content in periurethral tissues
   • Fatty infiltration of levator ani
   • Mitochondrial dysfunction in rhabdosphincter

4. Hormonal Effects:

   • Oestrogen receptors (ER-alpha, ER-beta) present throughout lower urinary tract
   • Oestrogen deficiency causes urethral mucosal atrophy
   • Loss of periurethral vascular plexus "cushioning"
   • Decreased urethral closure pressure by 15-30 cmH2O post-menopause

5. Neuromuscular Junction:

   • Pudendal nerve denervation (stretch injury during delivery)
   • Incomplete reinnervation with motor unit remodelling
   • Decreased motor unit recruitment on EMG

The Physics of Leakage

Understanding the pressure dynamics is essential for examination purposes.

Continence Equation:

• Continence maintained when: P(urethral closure) > P(intravesical)
• Maximum urethral closure pressure (MUCP) = P(urethral) - P(bladder)
• Normal MUCP at rest: 50-100 cmH2O (decreases with age)

During Stress Event (Cough):

• Normal: Pressure transmitted equally to bladder and proximal urethra
• The urethra is compressed against the supportive hammock
• Net pressure differential unchanged, continence maintained

In SUI:

• Pressure transmission ratio (PTR) to urethra reduced (less than 90%)
• Bladder pressure rises more than urethral pressure
• When differential exceeds closure pressure, leakage occurs

Clinical Pearl: "The Knack": Physiotherapy teaches patients to voluntarily contract the pelvic floor muscles immediately before a predictable stress event (cough, sneeze, lift). This pre-emptive contraction:

1. Elevates the urethra into the zone of equal pressure transmission
2. Increases intraurethral pressure through rhabdosphincter contraction
3. Reduces incontinence episodes by up to 98% in motivated patients [9]

---

4. Clinical Presentation

Symptom Assessment

The cardinal symptom of SUI is the involuntary leakage of urine coincident with physical exertion, sneezing, or coughing. Careful history taking is essential to differentiate SUI from other types of incontinence.

Characteristic Features of SUI:

• Leak occurs simultaneously with the stress event (not delayed)
• Small volume, "spurt" or "squirt" pattern
• No preceding urge sensation
• Severity correlates with intensity of activity
• Typically dry at night (no nocturia or nocturnal enuresis)
• Worse when bladder is full

Symptom Grading (Sandvik Severity Index):

The Bladder Diary

A 3-day bladder diary (frequency-volume chart) is essential for diagnosis. Patients record:

• Time and volume of each void
• Fluid intake (type and volume)
• Episodes of leakage (activity, volume)
• Urgency episodes
• Pad usage

Interpreting the Diary:

Differential Diagnosis

Clinical Pearl: Mixed Urinary Incontinence (MUI): Present in up to 40% of women with SUI. Critical management principle: treat the most bothersome symptom first. Surgery for SUI can unmask or worsen OAB symptoms ("de novo urgency" occurs in 10-15% post-operatively). Conservative treatment of OAB should be optimised before surgical intervention for SUI. [10]

Physical Examination

A systematic examination is essential to confirm the diagnosis and identify associated conditions.

General Examination

• BMI calculation (obesity is modifiable risk factor)
• Chronic respiratory disease signs (cough)
• Neurological assessment (gait, lower limb reflexes if indicated)

Abdominal Examination

• Exclude palpable bladder (retention/overflow)
• Exclude abdominal masses
• Surgical scars (previous procedures)

Pelvic Examination

Position: Patient in dorsal lithotomy or left lateral with Sims speculum

Inspection:

• Vulval atrophy (pale, thin, loss of rugae) - suggests hypoestrogenism
• Excoriation or dermatitis (ammonia dermatitis from chronic wetness)
• Previous surgical scars

Prolapse Assessment (POP-Q Staging):

• Anterior wall (cystocele) - commonly coexists with SUI
• Posterior wall (rectocele)
• Apical (uterine/vault prolapse)
• Document POP-Q stage (0-IV)

Provocative Testing (Cough Stress Test):

1. Patient with comfortably full bladder
2. Ask patient to cough vigorously
3. Positive test: Immediate spurt of urine visualised at the urethral meatus
4. Timing: Leak simultaneous with cough (SUI) vs delayed leak (detrusor overactivity)

Bonney's Test (Modified):

1. Positive cough test confirmed
2. Place two fingers to elevate the bladder neck (simulating surgical support)
3. Repeat cough
4. Positive: Leak eliminated or significantly reduced
5. Interpretation: Predicts good response to surgical correction
6. Caution: May occlude urethra; test should elevate, not compress

Q-Tip Test (Cotton Swab Test):

1. Lubricated cotton-tipped applicator inserted into urethra to bladder neck
2. Angle measured at rest (horizontal reference)
3. Patient asked to strain (Valsalva)
4. Angle measured again
5. Positive: Change > 30 degrees indicates urethral hypermobility
6. Clinical utility: Limited; hypermobility does not always correlate with SUI

Pelvic Floor Muscle Assessment (Oxford Grading):

Most women with SUI demonstrate Oxford grade 1-2.

Red Flags Requiring Urgent Referral

• Haematuria (visible or non-visible): 2-week wait suspected cancer pathway
• Palpable bladder: Urinary retention with overflow
• Recurrent UTI (> 3/year): Exclude underlying pathology
• Pelvic mass: Ovarian/uterine malignancy
• Neurological symptoms: Cauda equina, MS, spinal cord pathology
• Previous pelvic radiotherapy: High surgical complication risk
• Pelvic pain: Consider interstitial cystitis, endometriosis

---

5. Investigations

Primary Care Investigations

All women presenting with SUI symptoms require baseline assessment before specialist referral.

Urinalysis (Dipstick)

• Leukocytes/Nitrites: UTI can mimic or exacerbate SUI; treat before assessment
• Blood: Haematuria requires urgent investigation (cystoscopy, imaging)
• Glucose: Undiagnosed diabetes mellitus causes polyuria

Urine Culture

• MSU if dipstick positive or recurrent symptoms
• Treat confirmed infection before definitive assessment

Post-Void Residual (PVR)

• Bladder ultrasound scan within 15 minutes of voiding
• Normal: less than 50ml
• Elevated: > 100ml suggests voiding dysfunction
• Significance: High PVR with incontinence suggests overflow; surgery may worsen retention

Specialist Investigations

Urodynamic Studies (UDS)

Urodynamics is the gold standard investigation for lower urinary tract dysfunction, providing objective diagnosis of SUI. [11]

Components of Multichannel Urodynamics:

1. Uroflowmetry:

   • Maximum flow rate (Qmax): Normal > 15ml/s
   • Voiding pattern: Continuous vs intermittent
   • Voided volume: Ideally > 150ml for interpretation

2. Filling Cystometry:

   • Detrusor pressure (Pdet) = Pves (intravesical) - Pabd (abdominal)
   • First sensation of filling: Normal 150-200ml
   • Strong desire to void: Normal 300-400ml
   • Maximum cystometric capacity: Normal 400-600ml
   • Detrusor overactivity: Involuntary detrusor contractions during filling
   • Urodynamic SUI: Leakage with increased abdominal pressure without detrusor contraction

3. Pressure-Flow Studies:

   • Assesses voiding function
   • Excludes bladder outlet obstruction

4. Valsalva Leak Point Pressure (VLPP):

   • The abdominal pressure at which leakage occurs during Valsalva
   • VLPP > 90 cmH2O: Urethral hypermobility (good surgical prognosis)
   • VLPP 60-90 cmH2O: Mixed mechanism
   • VLPP less than 60 cmH2O: Intrinsic sphincter deficiency (may need bulking/AUS)

5. Maximum Urethral Closure Pressure (MUCP):

   • Measured during urethral pressure profile
   • MUCP less than 20 cmH2O: Suggests ISD
   • Less reproducible than VLPP

When to Request Urodynamics (NICE NG123 Recommendations) [1]:

Urodynamic Findings in Different Conditions:

Exam Detail: Urodynamics Technical Points for Viva:

1. Preparation: Stop anticholinergics 5 days before; ensure no UTI
2. Catheter position: Rectal balloon for Pabd; 6Fr bladder catheter for Pves
3. Fill rate: 50-100ml/min (physiological less than 50ml/min if neuropathic)
4. Provocative manoeuvres: Cough, Valsalva, heel-bounce, running water
5. Quality control: Regular cough spikes equal on both channels; baseline correction

Artefacts to Recognise:

• Rectal contractions (isolated Pabd spikes)
• Catheter displacement (sudden pressure changes)
• Straining vs true detrusor contraction (Pabd rise vs Pdet rise)

Pad Test

Quantifies urine loss objectively.

1-Hour Pad Test (ICS Standardised):

1. Apply pre-weighed pad
2. Drink 500ml water over 15 minutes
3. Perform activities: walk, climb stairs, sit-stand (x10), cough (x10), run in place
4. Remove and weigh pad at 60 minutes

Interpretation:

24-Hour Home Pad Test: More representative of daily life; cutoff > 4g abnormal.

Cystoscopy

Not routinely indicated for SUI but required if:

• Haematuria (exclude bladder cancer)
• Recurrent UTI
• Suspected mesh complication (erosion)
• Suspected fistula
• Bladder pain symptoms

Imaging

Ultrasound:

• Transabdominal: PVR measurement, renal tract assessment
• Transvaginal/Transperineal: Mesh visualisation, bladder neck mobility

MRI Pelvis:

• Not routine for SUI
• Indicated for complex prolapse, suspected mesh complications, fistula assessment
• Research tool for levator ani assessment (avulsion defects)

---

6. Classification and Staging

ICS Standardisation (2002, Updated 2010)

The International Continence Society provides standardised terminology [1]:

Types of Urinary Incontinence:

• Stress urinary incontinence: Involuntary leakage on effort or exertion, or on sneezing or coughing
• Urgency urinary incontinence: Involuntary leakage accompanied by or immediately preceded by urgency
• Mixed urinary incontinence: Involuntary leakage associated with urgency and also with exertion, effort, sneezing, or coughing
• Postural incontinence: Involuntary leakage associated with change of body position
• Nocturnal enuresis: Involuntary leakage during sleep
• Continuous incontinence: Continuous involuntary leakage

McGuire Classification (ISD Severity)

Based on Valsalva Leak Point Pressure:

Blaivas-Olsson Classification

Severity Assessment (Ingelman-Sundberg)

---

7. Management

Overview of Treatment Algorithm

The management of SUI follows a stepwise approach, progressing from conservative to surgical options based on symptom severity, patient preference, and response to initial treatment. [1,2,12]

DIAGNOSIS CONFIRMED
        │
        ▼
┌───────────────────┐
│ CONSERVATIVE Rx   │ (First Line - 12 weeks minimum)
│ • Lifestyle       │
│ • PFMT           │
│ • Bladder training│
└───────────────────┘
        │
        ▼ Inadequate response
┌───────────────────┐
│ PHARMACOTHERAPY   │ (Second Line)
│ • Duloxetine     │
│ • Topical O2     │
└───────────────────┘
        │
        ▼ Inadequate response
┌───────────────────┐
│ SURGERY           │ (Third Line)
│ • Colposuspension │
│ • Fascial sling   │
│ • Bulking agents  │
│ • (MUS restricted)│
└───────────────────┘

Conservative Management

Lifestyle Modifications

Evidence supports lifestyle intervention as first-line management for all women with SUI. [8]

Weight Loss:

• The PRIDE trial demonstrated that 8% weight loss produces 47% reduction in weekly incontinence episodes [8]
• Every 5-unit reduction in BMI reduces SUI by approximately 50%
• Recommend 5-10% body weight loss over 6 months

Fluid Management:

• Total intake 1.5-2L/day (excessive intake worsens symptoms)
• Reduce caffeine (diuretic and bladder irritant)
• Limit alcohol (diuretic, sedative effect reduces awareness)
• Avoid fluids 2-3 hours before bedtime if nocturia present

Smoking Cessation: Triple impact on continence:

1. Chronic cough increases intra-abdominal pressure
2. Anti-oestrogenic effect accelerates urethral atrophy
3. Impaired collagen synthesis weakens pelvic floor "Surgery will not work if you continue smoking"

• essential counselling point

Bowel Optimisation:

• Constipation increases intra-abdominal pressure and weakens pelvic floor
• High-fibre diet, adequate hydration
• Correct defaecation posture (knees above hips, "squatty potty")
• Avoid straining (chronic Valsalva damages pelvic nerves)

Pelvic Floor Muscle Training (PFMT)

PFMT is the cornerstone of conservative SUI management with Level I evidence supporting its efficacy. The Cochrane review demonstrates that PFMT is more effective than no treatment or sham therapy, with cure rates of 40-60% for supervised programmes. [13]

Mechanism of Action:

1. Strengthens rhabdosphincter and levator ani
2. Improves reflex pelvic floor contraction before stress events ("The Knack")
3. Elevates bladder neck position
4. Increases urethral closure pressure

Optimal PFMT Protocol:

Teaching Correct Technique:

1. "Imagine you are stopping yourself from passing wind"
2. "Lift and squeeze, hold for 10 seconds, then relax for 10 seconds"
3. "Do not hold your breath, tighten your buttocks, or squeeze your thighs"
4. "Quick flicks"

• rapid contractions for reflex training

Common Errors:

• Breath-holding (Valsalva increases pressure)
• Gluteal/adductor co-contraction (not isolated)
• Bearing down instead of lifting
• Inadequate training duration (less than 8 weeks)
• Unsupervised exercises

Clinical Pearl: "The Knack" Technique: Teach patients to consciously contract the pelvic floor immediately BEFORE a predictable stress event. Studies show 98% reduction in leakage during coughing when "The Knack" is properly executed. [9] This compensatory mechanism can be learned within 1 week with proper instruction.

Vaginal Devices

Incontinence Pessaries:

• Silicone ring with integral "knob" (incontinence dish)
• Knob positioned behind symphysis pubis, elevates bladder neck
• Useful for activity-specific incontinence (sport, gym)
• Can be self-inserted for activities and removed afterward
• Cure rate approximately 50-70% during use

Disposable Intravaginal Devices:

• Single-use devices (e.g., Impressa, Uresta)
• Tampon-like insertion
• Compresses urethra against symphysis
• Useful for intermittent stress situations

Vaginal Oestrogen (for Atrophic Changes):

• Local oestrogen (cream, pessary, ring) restores urethral mucosa
• Improves urethral seal and mucosal coaptation
• Does not cure SUI alone but adjunctive benefit
• Safe in most breast cancer patients (minimal systemic absorption)
• NICE recommends offering to postmenopausal women with SUI [1]

Pharmacological Management

Duloxetine

Duloxetine is the only licensed medication for SUI in the UK (NICE recommends as second-line option). [1,14]

Mechanism:

• Serotonin-noradrenaline reuptake inhibitor (SNRI)
• Enhances pudendal nerve activity
• Increases rhabdosphincter tone and contractility
• Does not affect detrusor function

Efficacy:

• Reduces incontinence episode frequency by 50% (vs 27% placebo)
• Does not cure SUI; benefit lost when discontinued
• NNT = 8 for 50% reduction in episodes

Dosing:

• Start 20mg twice daily for 2 weeks
• Increase to 40mg twice daily if tolerated
• Review at 4-8 weeks
• Taper gradually if discontinuing (avoid withdrawal symptoms)

Side Effects (limit tolerability):

Contraindications:

• Concurrent MAOIs
• Uncontrolled narrow-angle glaucoma
• Severe hepatic impairment
• Severe renal impairment (CrCl less than 30ml/min)
• Pregnancy/breastfeeding

Patient Counselling: "This medication reduces leaks by about half but won't cure the problem. The main side effect is nausea, which usually improves after 2 weeks. If nausea is unbearable, we can stop it. Don't stop suddenly - taper over a week."

Other Medications (Limited Evidence)

Alpha-Adrenergic Agonists (historical):

• Phenylpropanolamine, ephedrine - withdrawn due to cardiovascular risks
• Midodrine - off-label use only, limited evidence

Oestrogen (Systemic):

• Cochrane review shows no benefit and possible worsening of UI with systemic HRT [15]
• Topical vaginal oestrogen is recommended for atrophic changes

Surgical Management

Surgery is indicated when conservative management has failed (typically after 12 weeks of supervised PFMT) and symptoms significantly impact quality of life. [1,12]

Exam Detail: The Mesh Controversy

Since 2018, vaginal mesh procedures for SUI (TVT, TOT) have been subject to significant restriction:

Timeline:

• 2018: NHS England "pause" on vaginal mesh for stress incontinence and prolapse
• 2019: NICE guidance update reflecting concerns
• 2020: Cumberlege Report ("First Do No Harm") highlighted patient suffering
• 2024: Continued restriction with high-volume specialist centre requirement

Complications of Synthetic Mid-Urethral Slings:

• Mesh erosion/exposure (2-10%)
• Chronic pain (5-10%)
• Dyspareunia (5-15%)
• Voiding dysfunction (5-10%)
• De novo urgency (10-15%)
• Mesh removal required (3-5%)

Current Regulatory Status (2024):

• UK: "Pause" continues; only in specialist centres with MDT
• USA: FDA reclassification; ongoing litigation
• Europe: Variable by country; stricter consent requirements
• Australia/NZ: High scrutiny; autologous alternatives preferred

Implications for Practice:

• Detailed consent process required (30+ minutes)
• Document discussion of ALL alternatives
• MDT involvement mandatory
• Only performed by specialist surgeons with declared outcomes

Burch Colposuspension

The Burch colposuspension was the historical gold standard before synthetic slings. It has returned to prominence following mesh restrictions. [12,16]

Mechanism:

• Sutures placed in paravaginal fascia on either side of bladder neck
• Sutured to Cooper's ligament (pectineal ligament on pubic bone)
• Elevates and supports the anterior vaginal wall and bladder neck
• Restores the "hammock" support mechanism

Technique (Open or Laparoscopic):

1. Pfannenstiel incision (open) or port placement (laparoscopic)
2. Enter space of Retzius (retropubic space)
3. Identify bladder neck and paravaginal fascia
4. Place 2-3 permanent sutures each side (vagina to Cooper's ligament)
5. Cystoscopy to confirm no bladder/ureteral injury
6. Close in layers

Efficacy:

Complications:

Advantages:

• Well-established, long-term data
• No synthetic mesh
• Can combine with abdominal hysterectomy

Disadvantages:

• Major surgery (general anaesthesia, hospital stay)
• Longer recovery than MUS (6 weeks)
• Risk of enterocele/rectocele (compensatory prolapse)

Autologous Fascial Sling

Using the patient's own tissue eliminates mesh-related complications while achieving excellent cure rates. [17]

Tissue Harvest Options:

1. Rectus fascia: Most common; harvested from lower abdominal incision
2. Fascia lata: From lateral thigh (if abdominal surgery contraindicated)

Technique:

1. Pfannenstiel incision
2. Harvest 1.5cm x 8-10cm strip of rectus fascia
3. Create vaginal incision under urethra
4. Pass fascial strip using needle passers (retropubic or transobturator)
5. Position sling at mid-urethra, tension-free
6. Close donor site and vaginal incision

Efficacy:

• Cure rates 85-90% at 5 years (comparable to synthetic slings)
• No mesh-specific complications

Complications:

• Donor site pain/hernia (rare, less than 2%)
• All standard sling complications (voiding dysfunction, de novo urgency)
• Longer operative time than synthetic slings

Urethral Bulking Agents

Bulking agents are injectable substances placed periurethrally to narrow the urethral lumen and improve coaptation. Ideal for ISD, frail patients, or those declining major surgery. [18]

Mechanism:

• Creates "cushions" around the urethra
• Improves mucosal coaptation
• Increases outflow resistance

Available Agents:

Technique:

1. Cystourethroscopy (local anaesthesia feasible)
2. Identify injection sites (3, 6, 9 o'clock or 4-point)
3. Transurethral submucosal injection
4. Continue until coaptation achieved (urethral lumen closes)
5. Day case procedure

Efficacy:

• Improvement rate: 60-70%
• Cure rate: 20-40%
• Duration: Variable; often requires repeat injections
• Best for ISD; less effective for hypermobility

Advantages:

• Minimally invasive (local anaesthetic option)
• Day case procedure
• No incision
• Low complication rate
• Repeatable

Disadvantages:

• Lower long-term success than surgery
• Often requires repeat procedures
• Cost of repeat injections

Mid-Urethral Slings (MUS) - Restricted Use

Synthetic mid-urethral slings remain highly effective but are subject to restriction. [2,12]

Types:

1. Retropubic (TVT): Tension-free vaginal tape; passes behind pubic bone
2. Transobturator (TOT/TVT-O): Passes through obturator foramen
3. Single-incision (mini-sling): Shorter tape, single vaginal incision

Efficacy (when performed):

• Objective cure: 80-90% at 1 year
• Subjective cure: 85-95%
• Long-term (5-10 years): 70-80%

Current Indications (UK, restricted):

• Failed conservative management
• Fully informed consent with documented discussion of alternatives
• Performed by specialist surgeon with declared outcome data
• MDT discussion documented
• Patient accepts mesh-specific risks

Surgical Decision-Making

Special Populations

Male Stress Urinary Incontinence

Predominantly post-prostatectomy (radical prostatectomy for prostate cancer). [19]

Prevalence:

• Immediate post-op: 50-80% (temporary)
• Persistent (> 12 months): 5-15%

Management Ladder:

1. PFMT (pre-operative and post-operative): Mainstay of conservative Rx
2. Male sling (for mild-moderate): Compresses bulbar urethra
   • Transobturator slings (Advance, Virtue)
   • Cure rate: 60-80% for mild-moderate SUI
3. Artificial Urinary Sphincter (AUS): Gold standard for severe SUI
   • Inflatable cuff around bulbar urethra
   • Pump in scrotum (patient activates to void)
   • Cure rate: 75-90%
   • Revision rate: 25% at 10 years

Pregnancy and Future Fertility

Pre-pregnancy counselling:

• Delay surgical intervention until family complete
• Pregnancy + vaginal delivery likely to cause recurrence
• Relaxin hormone softens pelvic floor supports

Management during pregnancy:

• PFMT throughout pregnancy
• Topical oestrogen not indicated
• Surgery contraindicated

Delivery after anti-incontinence surgery:

• Elective caesarean section generally recommended
• Protects surgical repair from delivery trauma
• No absolute contraindication to vaginal delivery (discuss risks)

Elderly/Frail Patients

• Conservative management remains first-line
• Bulking agents preferred if surgery indicated (minimally invasive)
• Increased complication risk with major surgery
• Consider goals of care and life expectancy
• Containment (pads) may be appropriate choice

---

8. Complications of Treatment

Conservative Treatment Complications

PFMT:

• Minimal risks
• Rare: exacerbation of prolapse symptoms, perineal discomfort

Duloxetine:

• Nausea (25%), dry mouth (15%), constipation (10%)
• Rare: serotonin syndrome (with concurrent serotonergic drugs)
• Withdrawal symptoms if stopped abruptly

Surgical Complications

Immediate Complications (0-30 days)

Delayed Complications (> 30 days)

Exam Detail: Voiding Dysfunction Post-Surgery

Voiding dysfunction is a significant complication requiring prompt recognition and management.

Definition: Post-void residual > 150ml or inability to void

Early Management (less than 2 weeks post-op):

1. In-out catheterisation to confirm retention
2. Trial of void after 24-48 hours catheter drainage
3. If persistent, teach clean intermittent self-catheterisation (CISC)
4. Most resolve within 4-6 weeks as swelling subsides

Late Management (> 6 weeks):

1. Confirm with urodynamics (obstruction vs acontractile bladder)
2. If obstructed: urethrolysis (sling division/removal)
3. CISC for long-term if no improvement
4. Warning: Sling division usually causes SUI recurrence

Risk Factors for Voiding Dysfunction:

• Pre-existing voiding symptoms
• Elevated pre-operative PVR
• Previous anti-incontinence surgery
• Concurrent prolapse repair
• Excessive sling tension (technique)

---

9. Prognosis and Long-Term Outcomes

Natural History (Untreated)

• SUI typically progressive without intervention
• Spontaneous remission possible (10-20%), especially in younger women
• Weight loss can produce sustained improvement
• Pregnancy often causes temporary worsening
• Menopause may exacerbate due to oestrogen deficiency

Treatment Outcomes

Recurrence

Risk Factors for Recurrence:

• Obesity (ongoing or weight regain)
• Smoking (continued)
• Chronic cough (COPD, poorly controlled asthma)
• Constipation (chronic straining)
• High-impact activities (running, jumping)
• Pregnancy after surgery
• Ageing (progressive tissue weakness)

Management of Recurrent SUI:

1. Confirm diagnosis (urodynamics essential)
2. Exclude mesh complications if previous MUS
3. Optimise modifiable risk factors
4. Consider repeat procedure (different approach if prior failure)
5. MDT discussion for complex cases
6. AUS consideration for severe recurrent ISD

Quality of Life Impact

Studies consistently demonstrate significant improvement in quality of life following successful SUI treatment. [3,20]

Validated Quality of Life Measures:

• ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)
• ICIQ-UI (Urinary Incontinence module)
• KHQ (King's Health Questionnaire)
• PISQ (Pelvic Organ Prolapse/Incontinence Sexual Questionnaire)

Domains Affected:

• Physical activity limitation
• Social interaction avoidance
• Sexual function impairment
• Psychological impact (depression, anxiety, embarrassment)
• Occupational impact
• Sleep quality (if nocturnal symptoms)

---

10. Prevention and Screening

Primary Prevention

Obstetric Interventions:

• No conclusive evidence that elective caesarean section prevents long-term SUI
• Antenatal PFMT reduces postpartum incontinence (short-term)
• Avoid prolonged second stage if possible
• Careful instrumental delivery technique

Lifestyle:

• Maintain healthy weight (BMI less than 25)
• Smoking cessation
• Regular moderate exercise (avoid extreme high-impact)
• Early treatment of chronic cough
• Avoid chronic constipation

Secondary Prevention (After Treatment)

• Continue PFMT long-term (maintenance)
• Maintain healthy weight
• Smoking cessation essential
• Avoid heavy lifting for 6 weeks post-surgery
• Graduated return to exercise

Screening

• No population screening recommended
• Opportunistic enquiry during well-woman visits
• Targeted questioning in high-risk groups (postnatal, menopausal)
• "Do you ever leak urine when you cough, sneeze, or exercise?"

---

11. Guidelines Summary

NICE NG123 (2019, Updated 2024)

Key recommendations from the National Institute for Health and Care Excellence: [1]

1. Initial Assessment:

   • Bladder diary for minimum 3 days
   • Urinalysis to exclude infection/haematuria
   • Assess for prolapse and pelvic floor strength

2. First-Line Treatment:

   • Supervised PFMT for minimum 3 months
   • 8 contractions, 3 times daily
   • Must be supervised by specialist physiotherapist

3. Lifestyle:

   • Caffeine reduction if excessive intake
   • Weight loss if BMI > 30
   • Smoking cessation advice

4. Duloxetine:

   • Offer as second-line if surgery declined or contraindicated
   • Not first-line due to side effects

5. Surgery:

   • After failed conservative management
   • Discuss all options including native tissue procedures
   • Synthetic mesh: only if woman informed of risks, MDT discussed, specialist centre

6. Urodynamics:

   • Before surgery if diagnosis unclear
   • Before surgery in women with OAB symptoms
   • Before repeat surgery for recurrence

ICS/IUGA Guidelines

International Continence Society and International Urogynecological Association recommendations: [2]

• Multi-domain assessment (symptoms, QoL, goals)
• Shared decision-making essential
• Consider patient preferences and values
• Long-term follow-up after surgery

EAU Guidelines (European Association of Urology)

• Strong recommendation for PFMT as first-line
• Bulking agents for selected patients with ISD
• Surgical options individualised based on urodynamic findings
• Mesh procedures under strict governance

---

12. Viva and Examination Preparation

Opening Statement

"Stress urinary incontinence is defined as the involuntary leakage of urine on effort, exertion, sneezing, or coughing. It is the most common type of incontinence in women, affecting approximately 25-45% of adult women to varying degrees. The underlying mechanism involves either urethral hypermobility due to loss of pelvic floor support, or intrinsic sphincter deficiency. Management follows a stepwise approach: conservative measures including supervised pelvic floor muscle training for a minimum of 3 months as first-line, followed by pharmacotherapy with duloxetine as second-line, and surgical options for those who fail conservative management."

Common Viva Questions

Q1: "What is the difference between urethral hypermobility and ISD?"

"These represent two distinct pathophysiological mechanisms of stress incontinence:

Urethral hypermobility involves failure of extrinsic support. The urethra and bladder neck descend during straining because the supporting 'hammock' of endopelvic fascia and levator ani is weakened. This is the more common mechanism, often following vaginal delivery. On examination, Q-tip testing shows angle change greater than 30 degrees, and VLPP is typically above 90 cmH2O. These patients respond well to surgical repositioning with colposuspension or slings.

Intrinsic sphincter deficiency represents failure of the urethral closure mechanism itself. The sphincter is weak or damaged, functioning as a 'drainpipe' with minimal resistance. Causes include previous surgery, radiotherapy, or advanced age. VLPP is low, typically below 60 cmH2O. These patients require procedures that narrow the urethral lumen, such as bulking agents or artificial urinary sphincter, as repositioning alone is insufficient."

Q2: "A 45-year-old woman has failed conservative management. How would you counsel her regarding surgical options?"

"I would approach this consultation systematically:

First, I would confirm the diagnosis with urodynamics, particularly if she has any OAB symptoms, as this affects surgical outcomes.

I would explain that current UK practice has restrictions on synthetic mesh due to complications reported in some patients. I would discuss the alternatives:

1. Colposuspension: Open or laparoscopic procedure that supports the bladder neck by suturing the paravaginal fascia to Cooper's ligament. Cure rates are 85-90% at one year. Recovery is 4-6 weeks. Risks include voiding dysfunction in 10-15% and de novo urgency in 10-15%.

2. Autologous fascial sling: Uses the patient's own rectus fascia, eliminating mesh-related risks. Similar cure rates to synthetic slings. Additional donor site discomfort but no mesh complications.

3. Bulking agents: Minimally invasive option, can be done under local anaesthetic. Lower cure rates (40-60%) and often requires repeat injections, but suitable for those wanting to avoid major surgery.

4. Synthetic mesh slings: Still available but require specialist centre, MDT discussion, and detailed consent process documenting that she understands mesh-specific risks including erosion, pain, and possible need for removal.

I would document this discussion thoroughly and allow time for questions and reflection."

Q3: "What are the essential components of urodynamics interpretation in SUI?"

"Urodynamics provides objective assessment of lower urinary tract function. The key components I would assess are:

1. Filling cystometry: I am looking for a stable detrusor (flat trace during filling). Any involuntary detrusor contractions indicate detrusor overactivity, which is mixed incontinence and may not respond fully to anti-stress surgery.

2. Leak with provocation: I perform cough and Valsalva testing. Leakage occurring simultaneously with the stress event, without detrusor pressure rise, confirms urodynamic stress incontinence.

3. Valsalva leak point pressure: This is the abdominal pressure at which leakage occurs. A VLPP greater than 90 cmH2O suggests hypermobility and predicts good surgical outcome. A VLPP below 60 cmH2O indicates intrinsic sphincter deficiency and may require bulking agents or AUS.

4. Voiding phase: I assess the pressure-flow relationship. If there are existing voiding symptoms or high residual volumes, surgery that increases outflow resistance may cause retention.

5. Maximum urethral closure pressure: Low MUCP (below 20 cmH2O) correlates with ISD and poorer surgical outcomes.

I would also check for artefacts such as catheter displacement and ensure quality control by verifying equal cough spikes on both channels."

Common Mistakes That Fail Candidates

• Recommending surgery without 12 weeks of supervised PFMT first
• Failing to mention urodynamics before surgery for mixed symptoms
• Not discussing mesh complications and alternatives during consent discussion
• Confusing SUI with OAB (stress vs urge incontinence)
• Forgetting to exclude red flags (haematuria, palpable bladder)
• Not mentioning weight loss as first-line intervention
• Recommending duloxetine as first-line treatment (it is second-line)

---

13. Patient Information

What is Stress Urinary Incontinence?

Stress urinary incontinence (SUI) means leaking urine when you cough, sneeze, laugh, exercise, or lift something heavy. It is extremely common - affecting about 1 in 3 women at some point in their lives. It is NOT a normal part of ageing that you simply have to accept.

What Causes It?

The urethra (the tube that carries urine from your bladder) is normally held closed by muscles and supporting tissues. When these supports are weakened (often from childbirth, menopause, or weight gain), the urethra cannot stay closed during activities that put pressure on your bladder.

What Can Help?

Most women improve significantly with simple measures:

1. Pelvic Floor Exercises: These strengthen the muscles that support your bladder. They work for about 6 out of 10 women - but you need to do them properly and regularly for at least 3 months. Ask your GP for referral to a specialist physiotherapist who can teach you the correct technique.

2. Weight Loss: If you are overweight, losing even 5-10% of your body weight can reduce leaking by half.

3. Lifestyle Changes: Reduce caffeine and fizzy drinks. Stop smoking. Treat constipation.

If exercises don't work:

• Medication (duloxetine): A tablet that can reduce leaking, but doesn't cure it and has side effects.
• Surgery: Several options exist to support the urethra. Your specialist will discuss which is most suitable for you.

When Should I See a Doctor?

• Blood in your urine (even once)
• Pain when passing urine
• Frequent infections
• Difficulty emptying your bladder
• A bulge or lump at your vagina

Support and Resources

• Bladder & Bowel Community: www.bladderandbowelfoundation.org
• NHS Squeezy App: Pelvic floor exercise reminder
• Continence Foundation of Australia: www.continence.org.au

---

14. References

1. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management (NG123). NICE; 2019 (Updated 2024). Available from: https://www.nice.org.uk/guidance/ng123

2. Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042. doi:10.1038/nrdp.2017.42

3. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130-140. doi:10.18553/jmcp.2014.20.2.130

4. DeLancey JO. Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. Am J Obstet Gynecol. 1994;170(6):1713-1720. doi:10.1016/s0002-9378(94)70346-9

5. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S; Norwegian EPINCONT study. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. J Clin Epidemiol. 2000;53(11):1150-1157. doi:10.1016/s0895-4356(00)00232-8

6. MacArthur C, Wilson D, Herbison P, et al. Urinary incontinence persisting after childbirth: extent, delivery history, and effects in a 12-year longitudinal cohort study. BJOG. 2016;123(6):1022-1029. doi:10.1111/1471-0528.13395

7. Chen B, Wen Y, Polan ML. Elastolytic activity in women with stress urinary incontinence and pelvic organ prolapse. Neurourol Urodyn. 2004;23(2):119-126. doi:10.1002/nau.20012

8. Subak LL, Wing R, West DS, et al.; PRIDE Investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481-490. doi:10.1056/NEJMoa0806375

9. Miller JM, Sampselle C, Ashton-Miller J, Hong GR, DeLancey JO. Clarification and confirmation of the Knack maneuver: the effect of volitional pelvic floor muscle contraction to preempt expected stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(6):773-782. doi:10.1007/s00192-007-0525-3

10. Richter HE, Albo ME, Zyczynski HM, et al.; Urinary Incontinence Treatment Network. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med. 2010;362(22):2066-2076. doi:10.1056/NEJMoa0912658

11. Rosier PFWM, Schaefer W, Lose G, et al. International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243-1260. doi:10.1002/nau.23124

12. Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017;7(7):CD006375. doi:10.1002/14651858.CD006375.pub4

13. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10(10):CD005654. doi:10.1002/14651858.CD005654.pub4

14. Mariappan P, Alhasso A, Ballantyne Z, Grant A, N'Dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol. 2007;51(1):67-74. doi:10.1016/j.eururo.2006.08.041

15. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10:CD001405. doi:10.1002/14651858.CD001405.pub3

16. Lapitan MCM, Cody JD, Mashayekhi A. Open retropubic colposuspension for urinary incontinence in women. Cochrane Database Syst Rev. 2017;7(7):CD002912. doi:10.1002/14651858.CD002912.pub7

17. Albo ME, Richter HE, Brubaker L, et al.; Urinary Incontinence Treatment Network. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med. 2007;356(21):2143-2155. doi:10.1056/NEJMoa070416

18. Kirchin V, Page T, Keegan PE, Atiemo KO, Cody JD, McClinton S. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev. 2017;7(7):CD003881. doi:10.1002/14651858.CD003881.pub4

19. Van Kampen M, De Weerdt W, Van de Winckel A, Claes H, Schuermans P, Van Poppel H. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. Lancet. 2000;355(9198):98-102. doi:10.1016/S0140-6736(99)03473-X

20. Sung VW, Borello-France D, Newman DK, et al.; NICHD Pelvic Floor Disorders Network. Effect of behavioral and pelvic floor muscle therapy combined with surgery vs surgery alone on incontinence symptoms among women with mixed urinary incontinence: the ESTEEM randomized clinical trial. JAMA. 2019;322(11):1066-1076. doi:10.1001/jama.2019.12467

---

Copyright (c) 2025 MedVellum. All rights reserved. This content is for educational purposes only and does not constitute medical advice.